switch NPH to glargin

Phase 3Small molecule

LLes Laboratoires des Médicaments Stériles

switch NPH to glargin is one of 47 small molecule programs targeting Efficacy and Safety. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Efficacy and SafetyNot yet recruiting

Efficacy and SafetyPhase 3

Not yet recruiting

Competition

Competitive Landscape

242 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

1 2

Tuoyi

SSun Yat-sen University

Phase 3

4 3

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

3 4

Busulfex

Akero Therapeutics

Phase 3

3 5

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

1 6

Oxycontin

PPurdue Pharma LP

Phase 3

1 7

Giapreza

LLa Jolla Pharmaceutical Company

Phase 3

1 8

Alka-Seltzer

AAbbott

Phase 3

1 9

Mecobalamin

Eisai

Phase 3

1 10

Tegoprazan

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in Diabetic Tunisian Patients.

Not yet recruiting·LLes Laboratoires des Médicaments Stériles·Phase 4·NCT06999551·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for switch NPH to glargin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — switch NPH to glargin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for switch NPH to glargin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Les Laboratoires des Médicaments Stériles company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: LLes Laboratoires des Médicaments Stériles

switch NPH to glargin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News